Search Results - "Hardling, M."

THE REVII TRIAL: LENALIDOMIDE AND DEXAMETHASONE AS SECOND LINE TREATMENT IN MYELOMA FOLLOWED BY EXTENDED LENALIDOMID VS LEN/DEX by Lund, J., Gruber, A., Lauri, B., Blimark, C., Swedin, A., Hansson, M., Forsberg, Karin, Ahlberg, L., Carlsson, C., Waage, A., Gimsing, P., Vangsted, A. J., Frolund, U., Hardling, M., Mellqvist, U. H., Nahi, H.

Get full text

An investigation into whether deletions in 9p reflect prognosis in adult precursor B-cell acute lymphoblastic leukemia: a multi-center study of 381 patients by Nahi, Hareth, Hagglund, Hans, Ahlgren, Thomas, Bernell, Per, Hardling, Mats, Karlsson, Karin, Lazarevic, Vladimir Lj, Linderholm, Mats, Smedmyr, Bengt, Astrom, Maria, Hallbook, Helene

“…1 Department of Haematology, Karolinska University Hospital 2 Department of Haematology, Malmö University Hospital 3 Department of Haematology, Sahlgrenska…”
Get full text

Cryotherapy as prophylaxis against oral mucositis after high-dose melphalan and autologous stem cell transplantation for myeloma: a randomised, open-label, phase 3, non-inferiority trial by Johansson, Jan-Erik, Bratel, John, Hardling, Mats, Heikki, Lena, Mellqvist, Ulf-Henrik, Hasséus, Bengt

“…The conditioning therapy used in connection with haematopoietic stem cell transplantation (HSCT) can induce painful oral mucositis, which has negative impacts…”
Get full text

Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial by Jakobsen Falk, Ingrid, Lund, Johan, Gréen, Henrik, Gruber, Astrid, Alici, Evren, Lauri, Birgitta, Blimark, Cecilie, Mellqvist, Ulf-Henrik, Swedin, Agneta, Forsberg, Karin, Carlsson, Conny, Hardling, Mats, Ahlberg, Lucia, Lotfi, Kourosh, Nahi, Hareth

“…Purpose Despite therapeutic advances, patients with multiple myeloma (MM) continue to experience disease relapse and treatment resistance. The gene ABCB1…”
Get full text

The Rev II Trial: Lenalidomide and Dexamethasone As Second Line Treatment in Myeloma Followed By Extended Lenalidomid Vs Len/Dex by Lund, Johan, Karstorp, Sigrid, Alici, Evren, Gruber, Astrid, Lauri, Birgitta, Blimark, Cecilie, Swedin, Agneta, Hansson, Markus, Forsberg, Karin, Ahlberg, Lucia, Conny, Carlsson, Waage, Anders, Gimsing, Peter, Vangsted, Annette Juul, Frølund, Ulf Christian, Hardling, Mats, Mellqvist, Ulf-Henrik, Nahi, Hareth

“…Background The indication for use of lenalidomide in second line of therapy has been based upon two phase III studies comparing lenalidomide and dexamethasone…”
Get full text

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma by Lund, Johan, Gruber, Astrid, Lauri, Birgitta, Duru, Adil Doganay, Blimark, Cecilie, Swedin, Agneta, Hansson, Markus, Forsberg, Karin, Ahlberg, Lucia, Carlsson, Conny, Waage, Anders, Gimsing, Peter, Vangsted, Annette Juul, Frølund, Ulf, Holmberg, Erik, Gahrton, Gösta, Alici, Evren, Hardling, Mats, Mellqvist, Ulf‐Henrik, Nahi, Hareth

“…Lenalidomide (Len) plus dexamethasone (Dex) is approved for the treatment of relapsed or refractory multiple myeloma (RRMM). It is possible that single‐agent…”
Get full text

The impact of ABCB1 single nucleotide polymorphisms on the outcome in lenalidomide treated multiple myeloma patients by Falk, IJ, Lund, J, Green, H, Gruber, A, Alici, E, Lauri, B, Blimark, C, Mellqvist, UH, Swedin, A, Forsberg, K, Carlsson, C, Hardling, M, Ahlberg, L, Nahi, H, Lotfi, K

Get full text

Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate by Hardling, Mats, Wei, Yuan, Palmqvist, Lars, Swolin, Birgitta, Stockelberg, Dick, Gustavsson, Bengt, Ekeland-Sjöberg, Kerstin, Wadenvik, Hans, Ricksten, Anne

“…Survival among chronic myelogenous leukemia (CML) patients can be linked to the reduction in leukemic cell burden. Treatment with imatinib mesylate results in…”
Get full text